Biotechnology

PEGBIO CO-B

Pega Biopharmaceuticals' cornerstone investors extend lock-up period for the third time

Pega Biopharmaceutical's CR059 Research Abstract Selected for ADA Annual Meeting

PEGBIO CO-B released FY2025 9 Months earnings on March 23 (BJT), actual revenue HKD 0, actual EPS HKD -0.4359

PEGBIO CO-B released FY2025 Q3 earnings on March 23 (BJT), actual revenue HKD 0, actual EPS HKD -0.1623

PEGBIO CO-B released FY2024 Q3 earnings on March 23 (BJT), actual revenue HKD 0, actual EPS HKD -0.192

PEGBIO CO-B released FY2024 9 months earnings on March 23 (BJT), actual revenue HKD 0, actual EPS HKD -0.6504

PEGBIO CO-B released FY2024 Q4 earnings on March 23, 2026 (BJT), with actual revenue of HKD 0 and EPS of HKD -0.1853

PEGBIO CO-B released FY2025 Q4 earnings on March 23 After-Market (BJT), actual revenue HKD 0, actual EPS HKD -0.1651

PEGBIO CO-B released FY2025 Annual Earnings on March 23 After-Market (BJT), actual revenue HKD 0 (forecast HKD 0), actual EPS HKD -0.6018 (forecast HKD -0.538)

Paigebio Biopharma-B Narrowed Full-Year Loss to 208 Million Yuan in 2025

Pega Biopharma-B signs commercialization cooperation agreement with Shanghai Tengri Pharmaceutical for Piadacon

PEGBIO CO-B to Release FY2025 Annual Earnings on March 23, 2026 After-Market (BJT), Forecast Revenue HKD 0, EPS HKD -0.538

Pg Bio-Pharmaceutical-B Completes Placement Agreement

Parexel Biopharmaceutical-B's cornerstone investors extend lock-up period

Pegasus Biopharmaceuticals-B Places 5.136 Million Shares to Raise HK$300 Million

Pega Biopharma-B Secures Anchor Investor Lock-Up Commitment

SoftBank China Capital Reiterates Buy Rating on Pega Biopharma-B

Pegbio-B's Core Product PB-119 Approved for Marketing by NMPA

Pagbil Biopharmaceuticals-B's Core Product PB-119's New Drug Application Approved

Pega BioPharma-B and PDC FZ-LLC Enter into Exclusive License Term Sheet for PB-119 in the Middle East and Africa

HINSANG GROUP

RIVERINE CHINA

PASHUN INT RTS

BRAINAURORA-B

SOFTMEDX

GOLDENPOWER

ZHONGKE GROUP

VISION SYNERGY

GEMILANG INTL

GHPC

02565

513700

PegBio has submitted an updated list of directors and board committee roles to the Hong Kong Stock Exchange, effective May 19, 2026. Michael Min Xu continues as chairman and executive director, with Jiancun Zhang leading the Remuneration and Appraisal Committee. Xiangjun Zhou and Yangyang Chen are part of the Audit Committee, while Xiaojun Wang, Xiangjun Zhou, and Yuhong Xu hold other committee positions.

PUBT

Penghua CSI HK Connect Health Care Composite ETF

Pegbio files directors list with Hong Kong Stock Exchange

PegBio announced the resignation of independent director Xinpeng Fan, effective May 19, 2026, along with his role as audit committee chair. The board has nominated Liao Yik Lam as his replacement, pending shareholder approval. Liao, a partner at ZSZH (HK) Fuson CPA Limited, brings over 20 years of experience and will assume the audit committee chair position upon election.

HKEX

HKEX-R

Hong Kong Exchanges and Clearing (HKEX)

PegBio independent director Fan resigns, audit committee chair role to change

03336

07666

08299

03317

02513

01879

02577

02218

02585

JU TENG INTL(03336) fell 25.93%, with a trading turnover 184.1 Million HKD, and a year-to-date rose 40.2%. METIS TECHBIO-P(07666) fell 14.13%, with a trading turnover 177.5 Million HKD, and a year-to-date rose 91%. GT GOLD(08299) fell 11%, with a trading turnover 24.9 Million HKD, and a year-to-date fell 12.7%.

Top Gainers&Losers

JU TENG INTL

METIS TECHBIO-P

GT GOLD

XUNCE

KNOWLEDGE ATLAS

XIZHI TECH-P

INNOSCIENCE

ANDRE JUICE

MOKINGRAN

Top 10 HK Stock Losers (5.19)

PEGBIO CO-B rose 19.83%; Innovent Biologics rose 1.00%, with a transaction volume of HKD 188 million; CanSino Biologics rose 0.18%, with a transaction volume of HKD 173 million; BeiGene rose 1.71%, with a transaction volume of HKD 134 million; Kelun-Biotech rose 3.16%, with a market value of HKD 102 billion

HK Stock Alerts

INNOVENT BIO

AKESO

BEONE MEDICINES

SKB BIO

Hong Kong stock movement: PEGBIO CO-B rises 19.83%, with clear capital flow, market sentiment triggers volatility attention

06651

09993

09936

03268

02661

09929

02255

01300

02701

PEGBIO CO-B(02565) rose 66.31%, with a trading turnover 991.4 Million HKD, and a year-to-date fell 73%. 51WORLD(06651) rose 42.3%, with a trading turnover 2.5 Billion HKD, and a year-to-date rose 73.5%. RADIANCE HLDGS(09993) rose 13.31%, with a trading turnover 3.4 Billion HKD, and a year-to-date rose 62%.

51WORLD

RADIANCE HLDGS

XIMEI RESOURCES

MEIG

QINGSONG HEALTH

SEM HLDGS

HAICHANG HLDG

TRIGIANT

NSING TECH

Top 10 HK Stock Gainers (5.18)

02659

02575

01796

In the past hour, the Hong Kong stock market has shown a clear divergence, with the strong performance of the pharmaceutical sector attracting a significant inflow of funds, particularly in stocks like PEGBIO CO-B and BAO PHARMA-B, which have seen notable gains, indicating an increase in short-term enthusiasm. Meanwhile, technology stocks appear relatively weak, with the declines of METASPACEX and Yimu Group drawing market attention, suggesting a rapid switch of funds between different sectors. Overall volatility is high, and the sentiment of short-term traders is fluctuating, with a faster market rhythm. The stock with the largest movement in the past hour, PEGBIO CO-B, has surged by 23.15%, rapidly attracting funds under the influence of the pharmaceutical sector, leading to heightened short-term sentiment and drawing the attention of many investors. The strong performance of this stock seems to inject vitality into the entire sector, driving up other related stocks. Strong stocks include: 1. BAO PHARMA-B: up 18.49%, with continuous inflow of funds against the backdrop of increased market enthusiasm, showing impressive short-term performance. 2. XUANZHUBIO-B: up 16.00%, recent strong trends reflect market confidence in its future development. 3. Jingjiu Kangliao: up 15.87%, gaining favor from investors as the pharmaceutical sector becomes active. 4. Zhongke Group Holdings - New: up 15.38%, with significant short-term fund support amid high market sentiment. 5. Silu Di Pharmaceutical Co., Ltd.: up 15.12%, with the stock's rise reflecting optimistic expectations for the pharmaceutical industry

BAO PHARMA-B

XUANZHUBIO-B

METASPACEX

THAC GROUP

3D MEDICINES

CHINA STAR ENT

Hong Kong Stock Movement Update: Biopharmaceutical stocks rebound strongly, PEGBIO CO-B rises 23%, METASPACEX falls 15%

PEGBIO CO-B surged 23.15%; CanSino Biologics fell 5.99%, with a transaction volume of HKD 996 million; Innovent Biologics fell 1.83%, with a transaction volume of HKD 970 million; Kelun-Biotech fell 2.89%, with a transaction volume of HKD 440 million; BeiGene fell 2.45%, with a market capitalization of HKD 269.7 billion

Hong Kong Stock Movement: PEGBIO CO-B surged 23.15%, with clear capital flow; what is stirring the market sentiment?

02477

02940

02225

06869

02635

02726

02631

PEGBIO CO-B(02565) fell 18.5%, with a trading turnover 104.2 Million HKD, and a year-to-date fell 83.8%. WELLCELL HOLD(02477) fell 15.3%, with a trading turnover 362.7 Million HKD, and a year-to-date rose 38.8%. WELLCELL HOLD(02940) fell 14.83%, with a trading turnover 61.4 Million HKD, and a year-to-date rose 40.6%.

WELLCELL HOLD

JINHAI MED TECH

YOFC

NUOBIKAN

EPIWORLD

SICC

Top 10 HK Stock Losers (5.15)

PEGBIO CO-B fell 10.12%; Kintor Pharmaceutical-B fell 8.76%, with a transaction volume of HKD 622 million; Innovent Biologics fell 5.88%, with a transaction volume of HKD 527 million; CanSino Biologics fell 2.50%, with a transaction volume of HKD 191 million; BeiGene fell 2.65%, with a market value of HKD 276.8 billion

CARSGEN-B

Hong Kong Stock Movement: PEGBIO CO-B fell 10.12%, with clear capital flow, volatility attracting market attention

00991

03200

01921

02208

03858

00917

01818

02526

PEGBIO CO-B(02565) fell 29.59%, with a trading turnover 96.7 Million HKD, and a year-to-date fell 80.1%. DATANG POWER(00991) fell 13.96%, with a trading turnover 1.9 Billion HKD, and a year-to-date rose 36.7%. HANS CNC(03200) fell 12.27%, with a trading turnover 566.4 Million HKD, and a year-to-date rose 69.4%.

PEGBIO CO-B(02565.HK)